PT-141 vs Melanotan 2: Central versus Peripheral Melanocortin Research
Published 2026-06-11 · 6 min read
PT-141 (bremelanotide) and Melanotan 2 share a backbone and a receptor family, but they have come to occupy different corners of the melanocortin research literature. MT-2 is the parent compound; PT-141 was identified as one of its metabolites and developed as a separate research tool. The practical difference for designing a study is which receptor-mediated effect you want to recruit.
At a glance
| PT-141 | Melanotan 2 | |
|---|---|---|
| Compound class | Cyclic heptapeptide; α-MSH analogue | Cyclic heptapeptide; α-MSH analogue |
| Also known as | Bremelanotide | Melanotan-II; MT-II |
| Relationship | Identified as a metabolite of MT-II; developed as a separate research tool | Parent compound; PT-141 is its descendant |
| Structural difference | Lacks the C-terminal amide present in MT-II | Carries C-terminal amide |
| Receptor profile | Broad melanocortin agonist; research interest dominated by MC3R/MC4R activity | Broad melanocortin agonist across MC1R-MC5R |
| Pigmentation activity | Minimal in matched models | Marked MC1R-mediated pigmentation response |
| Primary research focus | Central nervous system signaling; preclinical sexual response circuitry | Pigmentation biology; melanocortin agonism across the receptor family |
| Typical research vial size | 10 mg | 10 mg |
Shared backbone, divergent research profiles
MT-2 is a broad melanocortin agonist with activity across MC1R-MC5R. Its most-cited research uses are in pigmentation biology, where MC1R agonism drives melanogenesis and a visible coat or skin response. PT-141 retains a similar core structure but lacks the C-terminal amide; in matched preclinical work it shows substantially weaker pigmentation activity while preserving central receptor engagement at MC3R and MC4R. That divergence is what made PT-141 a useful tool for research focused on the central melanocortin circuitry without confounding from peripheral pigmentation effects.
The receptors at issue
- MC1R — skin and melanocytes; pigmentation. Dominates the MT-2 research footprint.
- MC3R — hypothalamus and limbic system; energy and sexual response circuitry. Engaged by both, but its functional role is studied most often in PT-141 work.
- MC4R — central nervous system; appetite, energy balance, and CNS-mediated sexual response. Centerpiece of the PT-141 literature.
- MC5R — exocrine and adipose tissue; secondary research interest for both compounds.
For a deeper background on the pigmentation-focused family (Melanotan 1 and Melanotan 2), see Melanotan 1 vs Melanotan 2. For PT-141's standalone reference, see the PT-141 Reference Guide.
When to choose each
- Pigmentation is the endpoint: MT-2 is the primary tool. MC1R agonism is its dominant peripheral effect.
- Central MC3R/MC4R signaling is the endpoint: PT-141 cleanly engages central receptors without the visible pigmentation response.
- Pigmentation is a confound: behavioral or neuroendocrine designs in pigmented strains, where coat color changes would bias observer scoring. PT-141 is preferred.
- Receptor dissection: run both compounds alongside selective agonists (for example, Melanotan 1 as a more MC1R-selective comparator) to attribute observed effects to specific receptor arms.
Lab handling
Both compounds are lyophilized and stable at −20°C. Both reconstitute cleanly in bacteriostatic water without cosolvents. Standard practice applies: gentle swirling, aliquoting before freezing, and limiting freeze-thaw cycles. For step-by-step procedure, see How to Reconstitute BPC-157. For dilution math at the 10 mg vial size, see the Peptide Dilution Table.
For Research Use Only. Information presented for laboratory and research applications. Not medical advice and not a substitute for qualified scientific judgment.